
Highlights from IMW 2019



ANTONIO SPADANO

MRD negatività: *endpoint* terapeutico e/o regolatorio?

Comitato Scientifico Mario BOCCADORO Michele CAVO Maria Teresa PETRUCCI

Coordinatore Scientifico Michele CAVO




Disclosure

 I have no actual or potential conflict of interest in relation to this program/presentation.



MM: advances in therapy and outcome



*Year ranges represent the year of diagnosis.

Survival Years

Note: By linking to the SSA Master Death File, survival was measured as time from diagnosis date to the date of death obtained from the SSA, time from diagnosis date to the date of inpatient death, or time from diagnosis date to September 30, 2015; Survival estimates were presented for multiple myeloma patients diagnosed and treated during 2006-2012 (n=9,521).





Highlights from IMW 2019



The evaluation of response in MM has similarly evolved to parallel advances in therapy and outcome

Complete Response (CR)

- Negative serum and urine immunofixation
- <5% PCs in marrow



Stringent Complete Response (sCR)

- Normal FLC ratio
- No clonal plasma cells in marrow

MRD negative

- Flow negative MRD
- Sequencing negative MRD
- Imaging negative MRD

Highlights from IMW 2019

Kumar S. Lancet Oncol, 2016



What is the clinical data to date justifying the use of MRD?

Anderson KC. Blood Adv, 2017


Highlights from IMW 2019



ORIGINAL REPOR

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

Α в GEM2000 GEM2005MENOS65 Chemotherapy randomization Chemotherapy randomization VBMCP/VBAD VBMCP/VBAD/Btz TD VTD MRD (n = 117) MRD Busulfan 12 mg/kg Melphalan 200 mg/m² (n = 205) plus melphalan 140 mg/m² plus ASCT plus ASCT Mephalan 200 mg/m² plus ASCT MRD (n = 256)MRD (n = 226) < CR CR Interferon alfa-2b Thalidomide VT Median follow-up: 6.3 years Interferon/prednisone ASCT or mini-ALO Median follow-up: 12.7 years



Three clinical trials:

609 newly diagnosed pts

- GEM2000 and GEM2005 for transplant-eligible pts

JOURNAL OF CLINICAL ONCOLOGY


- GEM 2010 for transplant-ineligible pts

Highlights from IMW 2019



ORIGINAL REPORT

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials



Highlights from IMW 2019

19-20 novembre 2019 Bologna

JOURNAL OF CLINICAL ONCOLOGY



Depth of Response in Multiple Myeloma: A Pooled Analysis of JOURNAL OF CLINICAL ONCOLOGY Three PETHEMA/GEM Clinical Trials


95% CI Р HR 0.42 0.34 to 0.51 < .001 Overall Transplant eligible 0.45 0.36 to 0.55 < .001 0.24 0.12 to 0.50 < .001 Transplant ineligible ISS I 0.50 0.36 to 0.68 < .001 0.34 to 0.59 < .001 ISS II 0.45 0.32 0.20 to 0.51 < .001 ISS III 0.44 0.33 to 0.59 < .001 Standard-risk FISH 0.30 0.16 to 0,58 < .001 High-risk FISH 1.2 0.0 0.2 0.4 0.6 0.8 1.0 Reduced Risk After MRD-HR 95% CI Ρ 0.55 to 0.81 0.67 < .001 Overall 0.59 to 0.90 .003 Transplant eligible 0.73 0.33 0.20 to 0.56 < .001 Transplant ineligible 0.72 0.52 to 0.99 .045 ISS I 0.54 to 0.96 ISS II 0.72 .028 0.59 0.38 to 0.93 .024 ISS III 0.56 to 0.98 0.74 .034 Standard-risk FISH 0.52 to 1.78 .917 High-risk FISH 0.97 0.0 0.2 0.4 0.6 0.8 1.0 1.2 Reduced Risk After CR

Highlights from IMW 2019





Minimal residual disease predicts superior survival in patients with multiple myeloma: a meta-analysis




Highlights from IMW 2019





Minimal residual disease predicts superior survival in patients with multiple myeloma: a meta-analysis




Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Highlights from IMW 2019





Minimal residual disease predicts superior survival in patients with multiple myeloma: a meta-analysis




Numbers at risk:

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Highlights from IMW 2019

19-20 novembre 2019 Bologna

 Numbers at risk:



Highlights from IMW 2019






HHS Public Access


Bone Marrow Transplant. Author manuscript; available in PMC 2017 August 25.

Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis



Highlights from IMW 2019


MRD: independence from treatment



Dimopoulos M. Haematologica, 2018

Highlights from IMW 2019


CASTOR



Spencer A. Haematologica, 2018



MRD: PFS based on sustained MRD negativity



PF5, progression-free survival.; MRD, minimal residual disease; DARA, daratumumab; D-Vd, daratumumab/bortezomib/dexamethasone; D-Rd, daratumumab/lenalidomide/dexamethasone; Vd, bortezomib/dexamethasone; Rd, lenalidomide/dexamethasone.


MRD negativity : 30% on Intention-to-treat; 16% sustained at 6m; 13% at 12m

Avet- Loiseau, HASH 2018, Poster 3272

Highlights from IMW 2019



MRD in HIGH RISK MM




Paiva B. Blood, 2016

Highlights from IMW 2019

Lahuerta J-J, JCO 2017



MRD: to evaluate maintenance therapy



Perrot A. Blood, 2018


36

42

23

Highlights from IMW 2019

MRD: to evaluate maintenance therapy



Highlights from IMW 2019



MRD: potential utility

- Prognostic factor (surrogate endpoint)
- To make treatment decisions
 - tool for defining the timing of treatment intervention
- To evaluate treatment efficacy




MRD: potential utility

- Prognostic factor (surrogate endpoint)
- To make treatment decisions
 - o tool for defining the timing of treatment intervention
- To evaluate treatment efficacy



When and how frequently to measure MRD?




Highlights from IMW 2019



MRD: useful as an endpoint for novel agents approval

In a disease with long natural history, the acceptance of MRD as a surrogate endpoint for regulatory purposes would enable much faster comparison between treatments, potentially translating into faster therapeutic development





Regulatory considerations for use of MRD in development of drug and biological products for treatment

- MRD should be assessed only in patients that are in CR
- The relationship between MRD and clinical benefit will need to be demonstrated in each disease setting (newly diagnosed, nontransplant eligible, relapsed refractory)
- Imaging techniques could be used in combination with MRD to assess response in extramedullary disease

Hematologic malignancies FDA 2018

Highlights from IMW 2019



i²TEAMM

International Independent Team for Endpoint Approval of Myeloma MRD

Objectives

- To evaluate and validate MRD as a surrogate endpoint of progression-free survival in multiple myeloma clinical trials through prospectively planned meta-analytic surrogacy analysis based on individual patient data
- To create an integrated meta-database (Mayo Clinic as independent Statistics and Data Coordination Center)
- 14 clinical trials: NDMM, RRMM, young, elderly, MRD after induction, after ASCT, after consolidation, during maintenance, methods: 1st generation flow (10⁻⁴), 2nd generation flow (10⁻⁵) or NGF (10⁻⁶), few studies NGS/ PCR, CR or > VGPR, > PR,

Highlights from IMW 2019



MRD: potential utility

- Prognostic factor (surrogate endpoint)
- To make treatment decisions
 - tool for defining the timing of treatment intervention
- To evaluate treatment efficacy



MRD in MM: unanswered question


While elimination of detectable MRD has been shown to be a prognostic marker in MM, therapeutic decisionmaking based on MRD has <u>NOT</u> been tested in prospective trials and is <u>NOT</u> yet the standard of care

Bal S. BJH, 2019

Highlights from IMW 2019



Using MRD for making treatment decisions



Kenneth C.A. Clin Cancer Res, 2017

Highlights from IMW 2019



Key ongoing or planned studies using MRD as a tool for eligibility or stratification

Study identifier – trial title	Population	Phase	Group/ Sponsor	Planned N	MRD methodology/ threshold	MRD threshold for eligibility	Intervention	Primary endpoint
NCT03901963 – A Study of Daratumumab Plus Lenalidomide vs. Lenalidomide Alone as Maintenance Treatment in Participants with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant	NDMM post-ASCT	3	Janssen	214	NGS/<10 ⁻⁵	MRD- positive after ASCT	Lenalidomide vs. Lenalidomide + subcutaneous daratumumab for 36 cycles	Percentage of patients with MRD $< 10^{-5}$
NCT03697655 – Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma	Relapsed	2	Polish Myeloma Consortium	274	MFC/<10 ⁻⁵	MRD-negative after last line of therapy with re-appearance of MRD	Daratumumab vs. Observation for MRD reappearance up to 73 weeks	EFS in Daratumumab vs. observation
S1803-Phase III study of Daratumumab/ rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC study)	NDMM post-ASCT	3	SWOG	TBD	NGS/<10 ⁻⁶	MRD-negative after 24 months post- ASCT maintenance therapy	Continue vs. stop maintenance with Lenalidomide or Lenalidomide + Daratumumab/ rHuPH20 (based on initial randomization)	Compare OS between continuation of maintenance therapy vs. discontinuation of maintenance
NCT03490344- Short Course Daratumumab in Patients With Multiple Myeloma	NDMM post induction	2	MSKCC	25	MFC/<10 ⁻⁶	MRD-positive after induction (±ASCT) or MRD re- appearance after being MRD negative to prior line of therapy	Daratumumab IV + Lenalidomide for 6 months	MRD negative (<10 ⁻⁶) after 6 months of therapy
NCT02969837 – Study of Initial Treatment with Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma	NDMM	2	University of Chicago	55	NGS/<10 ⁻⁶	MRD positive after induction with Elo- KRd x6	Additional Elo-KRd x6 followed by Elo-Rd maintenance	MRD negative (<10 ⁻⁵) after 8 months

Highlights from IMW 2019



Conclusions

MRD is a powerful prognostic factor

MRD is the most appealing candidate as surrogate endpoint for drug development and approval

Future studies should link MRD to decision points as to how to manage the different phases of treatment

It's time for an MRD-based treatment in MM

Highlights from IMW 2019



grazie

Highlights from IMW 2019